A fundamental issue in organogenesis is how dichotomous fate decisions are made securing proper allocation of multipotent progenitors to their respective descendants. Previous lineage tracing analyses showing Isl1 + / VEGFR2 + cardiac progenitors in the second heart field give rise to both endocardium and myocardium suggest VEGF plays a role in this fate decision, conceivably promoting an endocardial fate. Isl1 + multipotent progenitors and lineage-committed descendants thereof were visualized and quantified within their transition zone in the outflow tract. Forced VEGF expression during the critical E8.5-E10.5 interval tilted the balance between myocardial-and endocardial-committed progenitors towards the latter, culminating in generation of surplus endocardium developing at the expense of a much thinner myocardium. Experiments ruled-out that surplus endocardium is due to VEGF-induced endocardial proliferation and that reduced myocardium is due to myocardial apoptosis. Inducing VEGF after most Isl1 + progenitors have been exhausted had no effect on the normal endocardia/ myocardial ratio but instead produced an unrelated coronary phenotype. Together, these results uncover a novel role for VEGF in controlling proper allocation of Isl1 + cardiac progenitors to their respective descending lineages.
Introduction
All heart chambers share a basic structure of an inner single layer of endocardium and several layers of surrounding myocardial cells. The multiple embryonic origins of cardiac cells have been the subject of intense research over the past decades and a general picture of different cardiac progenitor cells (CPCs), their embryonic sources, and their relative contributions to mature myocardium and endocardium has emerged and continues to be further refined [For selected comprehensive reviews on CPCs see (Brade et al., 2013; Di Felice and Zummo, 2013; Evans et al., 2010; Garry and Olson, 2006; Lints et al., 1993; Martin-Puig et al., 2008) ]. A key advance in CPC research has been the identification of multipotent CPCs, including of progenitors with the potential to form all major cell types in the heart. For the second heart field (SHF) of major significance are Isl1 + multipotent progenitors giving rise to cardiomyocytes, smooth muscle, and endocardial cells (Cai et al., 2003; Laugwitz et al., 2008; Sun et al., 2007) . Isl1 + progenitors, albeit not the sole contributors to the cardiac wall, were shown to contribute to the majority of cells in the right ventricle and atria and to a lesser extent also the left ventricle (Cai et al., 2003) . The fact that Isl1 + progenitors give rise to both myocardium and endocardium was repeatedly demonstrated in vivo using Isl1-Cre mediated lineage-tracing analysis and was also corroborated ex vivo in studies following the differentiation of embryonic stem cells (Cai et al., 2003; Moretti et al., 2006) . Notably, clonal analysis of ES-derived cells has confirmed that both cardiomyocytes and endocardial cells can indeed be generated from a single Flk1 + progenitor cell (Kattman et al., 2006; Misfeldt et al., 2009) .
A general issue concerning multipotent progenitors, including CPCs is how proper fate decisions are regulated securing a proper relative allocation to the respective descending lineages. Addressing this issue first requires identifying immediate lineage committed descendants at the bifurcation site. ES-based studies have pointed at the Nkx2. + marker combinations as identifiers of descending lineage-specific progenitors committed for muscle-and endocardium differentiation, respectively (Brade et al., 2013; Misfeldt et al., 2009; Moretti et al., 2006; Yang et al., 2008) . It should be mentioned, however, that an early, transient Nkx2.5 expression was also noted in certain endocardial subsets (Ferdous et al., 2009; Nakano et al., 2013; Stanley et al., 2002) . Putative lineage-committed progenitors expressing these marker combinations were also reported in vivo for E8.25 embryos (Moretti et al., Mechanisms of Development 142 (2016) [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] Abbreviations: A, atrium; CPCs, cardiac progenitor cells; C-Casp3, cleaved caspase-3; GOF, gain-of function; HPF, per high power field; IB4, Isolectin B4; ISH, in situ hybridization; LOF, loss-of-function; MHC, myosin heavy chain; MHCα, myosin heavy chain-α; OFT, outflow tract; PBS, phosphate buffered saline; SHF, second heart field; SPF, specific pathogen-free; V, ventricle. 
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Mechanisms of Development j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / m o d 2006). Yet, the topology and dynamics of presumed transitions have not been elucidated. Here we visualized consecutive stages in CPC differentiation naturally taking place at the 'commitment zone' within the outflow tract (Jain et al., 2015) . This has provided us with a suitable experimental platform to examine how a particular candidate factor, namely VEGF, may impact these fate decisions.
Vascular Endothelial Growth Factor is mostly known for its angiogenic function (Carmeliet et al., 1996; Carmeliet et al., 1999) but numerous studies have extended the range of VEGF activities to include activities mediated by direct VEGF signaling in non-vascular cells expressing cognate VEGF receptors [for a review see (Crivellato, 2011; Licht and Keshet, 2013) ]. In the developing heart, VEGF was shown to play a role in several processes, including in ventricular trabeculation, endocardial cushion formation, heart septation and coronary angiogenesis. Severe cardiac abnormalities caused by experimental VEGF over-or under-expression have further led to the proposition that perturbations in normal VEGF dosage during critical stages of heart development might contribute to congenital heart defects (Carmeliet et al., 1996; Carmeliet et al., 1999; Dor et al., 2001; Ferrara et al., 1996; Miquerol et al., 2000; Scherptong et al., 2012) .
Expression of VEGF receptor 2 (Flk1/KDR) on Isl1 + CPCs renders them potentially directly responsive to VEGF thus prompting the proposition examined herein that VEGF may play a natural role in early CPCs' fate decisions, presumably in promoting an endocardial cell fate. In keeping with this proposition, previous findings have shown that VEGF induces endothelial specification of cultured human ES-derived Isl1 + progenitors . In addition, intra-myocardial injection to an adult heart of a synthetic modified VEGF mRNA resulted in directed differentiation of endogenous heart progenitors . Importantly, deletion of the major VEGF signaling receptor VEGFR 2 results in complete absence of endocardium (Shalaby et al., 1995) . Early embryonic lethality associated with this manipulation (Shalaby et al., 1995) , however, precludes using a VEGF loss-of-function (LOF) approach for distinguishing a role for VEGF in endocardial commitment from a role in endocardial maintenance. Notably, selective ablation of VEGFR2 from distinct CPC populations altered the relative contribution of the respective populations to the endocardium reflecting the heterogeneous origins of the endocardium (MilgromHoffman et al., 2011) . Herein, we used a conditional VEGF gain-of function (GOF) approach to address this question reasoning that increased VEGF levels at the transition zone beyond its developmentally-programmed level during the critical time where fate decisions are made might tilt the balance towards an endocardial commitment at the expense of myocardial commitment. Considering that descendants of Isl1 + CPCs account for N 90% of cells within the right ventricle and N 60% of atrial cells (Cai et al., 2003) , we further anticipate that this perturbation might culminate in an expanded endocardium developing at the expanse of a reduced myocardium. We show that excessive VEGF, indeed, skews the allocation of Isl1 + CPCs in favor of an endocardial fate, culminating in a distorted myocardium/endocardium stoichiometry. (Brade et al., 2013; Misfeldt et al., 2009; Moretti et al., 2006; Yang et al., 2008) . Aiding this triple co-staining analysis readily interpretable was the nuclear localization of the two transcription factors examined and the different, membrane localization of Flk1 (see Fig. 1A for a general scheme and for representative examples of the discernable five cell types). In the E10.5 heart triple-positive cells were found to be mostly restricted to the outflow tract (OFT), a locale previously reported in a study employing a lineage tracing approach to detect Isl1 + progenitors (Cai et al., 2003) . Importantly, our in situ analysis also allowed direct visualization of the respective lineage-restricted progenitors in the vicinity of bipotent progenitors (Fig. 1B, left image) . Defining a specific zone within the OFT where fate decisions take place made it possible to determine whether and how a given factor may affect bipotent progenitor commitments.
Results

2
Endogenous VEGF expression in the OFT
A prerequisite in the presumption that VEGF plays a role in fate decisions of bipotent cardiac progenitors is that VEGF is naturally expressed at the transition zone at the relevant time. VEGF, RNA in situ hybridization ( Fig. S1 ) and VEGF immunostaining showed that VEGF is indeed produced at the relevant time and zone within the OFT (Fig. 1B , right image), thereby allowing, in principle, a paracrine interaction with nearby progenitors expressing cognate VEGF receptors. Noteworthy, VEGF is also expressed in differentiated cardiomyocytes distributed in ventricles and atria in patterns compatible with its previously reported roles in heart development, such as a regulatory role in endocardial cushion formation (Dor et al., 2001 ) and an instructive role in formation of coronary vasculature (Wu et al., 2012) .
Delineating the topology and dynamics of Isl1 + CPCs differentiation
To examine possible roles of VEGF in endocardial/myocardial development, it was first necessary to delineate consecutive stages in CPCs differentiation in situ. To provide a comprehensive view of progression from bipotent progenitors to lineage committed progenitors and then to terminally differentiated cells of both lineages, we immuno-stained the whole heart with the three markers described above ( Fig. 2A I) . Focusing on the OFT, 3D reconstructions of Z-stacked confocal images was used to reveal distribution patterns of the respective cell types. A clear advantage of analyzing wholemount OFT preparations was that, in conjunction with the use of RGB (red/green/blue)-marked antibodies, it allowed identification of bipotent progenitors 'at a glance' due to the fact that only overlay of triple-positive cells could yield a white color. This identification was verified by inspecting 2 μm-thick optical sections thereof and observing the correct configuration of a yellow nucleus and a blue membrane as illustrated in Fig. 1A above. Triple-positive bipotent progenitors were not uniformly distributed throughout the OFT but rather found clustered at its distal region. Different fate decisions made by triple-positive progenitors could be readily discerned because a myocardial commitment is expected to appear in wholemount reconstructions as a white-to-yellow transition (due to Flk1 loss), whereas endocardial commitment should be evidenced as a white-to-purple transition (due to Nkx2.5 loss). Both transition types were indeed observed and, as expected, in a mutually exclusive manner. Thus, in some OFT domains, white cells were directly succeeded by columns of yellow stretches while in others, white cells were succeeded by purple cellular stretches ( Fig. 2A II) . Again, thin sections verified in both cases the expected marker constellation at the single cell level. Subsequent progenitor differentiation to mature myocardial or endocardial cells was evident as transition from the respective double-positive to the respective single-positive cells taking place further away in the same cellular succession. This linear differentiation cascade (schematized in Fig. 2A III) was further corroborated using serial OFT cross-sections (Fig. 2B ). These findings provide topological support to findings based on lineage tracing analyses showing that Isl1 + progenitors eventually give rise to both myocardium and endocardium (Cai et al., 2003; Laugwitz et al., 2008; Sun et al., 2007) , as well as provide a visual platform for examining factors that may impact these dichotomous cell decisions.
A conditional transgenic system for ectopic VEGF induction in the developing heart
To examine whether perturbations in normal VEGF dosage in the transition zone at a time where fate decisions are made might skew the normal relative allocation of myocardial and endocardial lineages, we used a VEGF over-expression strategy employing a bi-transgenic system designed for heart-specific, conditional VEGF induction. Briefly, a tetracycline-regulated VEGF 165 was conditionally induced in the heart using a myosin heavy chain-α promoter (MHCα) promoter to drive expression of a trans-activator protein. Because the MHCα promoter is active from E7.5 and onwards (Lyons et al., 1990) , use of this driving promoter allowed induction of ectopic VEGF during the critical developmental interval of E8.5-E10.5 (see experimental scheme in Fig. 3A and 'Experimental procedures' for further details). Quantification of cardiac VEGF mRNA by qPCR (not shown) and cardiac VEGF protein by ELISA (Fig. 3B ) indicated robust induction of transgenic VEGF. In situ VEGF mRNA analysis showed that transgenic VEGF expression was confined to the same cells producing endogenous VEGF with no evidence of expression in ectopic sites. Analysis also secured that VEGF is over-expressed in the relevant OFT region (Fig. S1) . 
VEGF over-expression skews bipotent progenitor's allocation in favor of endocardial-committed progenitors
To examine phenotypes resulting from VEGF over-expression, VEGF was induced in the heart from the beginning of pregnancy. Because a significant increase in cardiac VEGF was first detected at E9.5, hearts were retrieved at E9.5, E9.75, E10.0 and E10.5 and processed for analysis of cardiac progenitors. A clear OFT effect was already detected at E9.75 and became more pronounced by E10.0. Phenotypic analysis at later than E10.5 was avoided due to confounding factors associated with + CPCs differentiation. A. I. Wholemount E10.5 wt heart triple stained with the indicated markers. Note OFT region appearing white due to superposition of multiple bipotent progenitors. II. 2 μm thick Z-stack confocal image from the wholemount shown in (I). Note sequential cell transitions evidenced as from white-toyellow-to-green stretches in the outer OFT layer and white-to-purple-to-blue stretches in the inner layer. Scale bar: 100 μm. III. Schematic representation of deduced spatial relationships between cell types. B. OFT cross-sections (2 μm) at the indicated levels, with section #1 and section #8 derived from the furthermost distal and proximal regions, respectively. apparent myocardial dilatation and rapid heart deterioration, likely the result of resultant obstruction of chambers architecture (see below). Forced over-expression of VEGF led to an overall reduction in numbers of OFT Isl1 + progenitors, including in the number of Nkx2.5 + / Isl1 + /Flk1 + cells (Fig. 3C&D) ). Compared to control littermates, a 2-fold change in their ratio in favor of endocardial progenitors was calculated (Fig. 3E) . In principle, imbalanced progenitor allocation should have been reflected in both a decreased fraction of myocardial progenitors and a parallel increase in the fraction of endocardial progenitors but only the former was clearly evident. A possible, albeit not proven, explanation is that VEGF also enhances terminal differentiation (and correspondingly Isl1 + loss) of endocardial progenitors thereby accounting for no increase in their steady-state number within the OFT. This prompted us to examine whether forced VEGF over-expression might eventually change the normal myocardial-to-endocardial stoichiometry in heart chambers to which Isl1 + progenitors are known to have a major contribution.
2.6. Skewed CPC allocation induced by VEGF over-expression culminates in surplus endocardium and markedly reduced myocardium
An anticipated result of a skewed allocation of bipotent progenitors in favor of an endocardial fate is an abnormally expanded endocardium developing on the expanse of a reduced myocardium. Based on lineage tracing analysis showing that descendants of Isl1 + progenitors contribute to the majority of cells within atria and the right ventricles (Cai et al., 2003) , we examined the myocardial and endocardial architecture of these chambers in VEGF-induced E9.5, E10.0 and E10.5 hearts.
Strikingly, patches of a surplus endocardium were found in all cases interspersed in both atria and the ventricle (Fig. 4A&B) . The unprecedented configuration of surplus endocardium was best appreciated from 3D reconstructions (Fig. 4B) . Importantly, excessive endocardial development was accompanied by insufficient myocardial development, evidenced by long stretches of abnormally thin myocardium in both atria and ventricle (highlighted by white asterisks in Fig. 4A&B ).
To provide a quantitative measure of myocardial-to-endocardial ratio, both cell types were enumerated in heart sections derived at the E8.5-E10.5 developmental interval. While in control littermates the myocardium/endocardium ratio steadily increased reaching the expected 5:1 ratio by E10.5, a relative myocardial deficit and endocardial surplus was progressively generated in VEGF-induced hearts culminating in half of the normal myocardium/endocardium ratio already by E10.0 (Fig. 4C&D) . Not surprisingly, this abnormal pattern of heart development was followed by severe heart dilatation already detectable by external inspection of E10.5 embryos (not shown) and resulting in embryonic lethality shortly thereafter.
Surplus endocardium is not due to VEGF-induced endocardial proliferation and reduced myocardium is not due to myocardial apoptosis
It could be argued that surplus endocardium is not necessarily due to a skewed progenitor allocation but rather the result of VEGF-induced proliferation of established Flk1 + endocardial cells. Likewise, it could be argued that myocardial deficit is due to reduced proliferation of differentiated cardiomyocytes. To address these possibilities, the proliferation status of both endocardium and myocardium was determined using Ki67 immuno-staining. A progressive natural decline in the fraction of proliferating endocardial and myocardial cells during the relevant E9.75-E10.5 was observed in all heart chambers. Importantly, however, there was no difference in the fraction of proliferating cells of either cell type between control and VEGF-induced littermates, thus arguing against these possibilities (Fig. 5A ). It could also be argued that apparent myocardial thinning is due to VEGF-induced myocardial 'toxicity' and apoptosis. To address this possibility, sections serial to those used in Fig. 5A were co-stained with the apoptosis marker cleaved caspase-3. No appreciable apoptosis (b 1%) could be detected in myocardium (nor in endocardium) until, and including, E10.0 (Fig. 5B ). In conjunction with the finding that by E10.0 a significant drop at the myocardium/endocardium ratio and myocardial thinning already took place (Fig. 4) , this result ruled out that reduced myocardium was caused by increased myocardial apoptosis. Noteworthy, increased apoptosis in VEGF-induced hearts from E10.5 and onwards was of a generalized nature, affecting myocardium and endocardium to the same extent, likely a reflection of general cardiac degeneration.
Delaying the onset of ectopic VEGF induction to E10.5 does not impair myocardium/endocardium balance but produces a coronary vessel phenotype
To provide further support for the idea that the VEGF-induced perturbations in heart wall composition described above are initiated at the progenitor level, the onset of VEGF induction was delayed to E10.5, i.e., to a stage in heart development where Isl1 + progenitors have already been committed [Isl1 + progenitors has cleared the OFT and ceased Isl1 expression by E9.0 (Sun et al., 2007) ]. VEGF ELISA performed on E12.5 and 13.5 embryonic hearts validated a robust induction of transgenic VEGF, exceeding by N10-fold the levels of VEGF naturally produced by cardiomyocytes at comparable ages (Fig. 6A) . FACS analysis was carried-out to determine the relative abundance of cardiomyocytes and endocardial/endothelial cells in control and VEGF-induced mice. Results showed no change in cardiomyocyte numbers, corroborating the finding of no VEGF toxicity towards cardiomyocytes. Yet a significant increase in numbers of CD31 + cells was observed (Fig. 6B) . In contrast to early VEGF onset, however, the latter was not associated with an endocardial phenotype which appeared normal. Instead, the increase in the number of CD31 + cell in VEGF-induced E13.5 hearts was attributed to increased coronary angiogenesis (Fig. 6C) , a finding compatible with previous findings showing that at these embryonic ages VEGF drives the formation of coronary arteries via endocardial sprouting angiogenesis (Wu et al., 2012) . Taken together, the study showed that VEGF might play different roles during different stages in heart development, uncovering a novel role in early fate decisions made by Flk1 + bipotent progenitors.
Discussion
Findings described above affirm previous lineage tracing analyses indicating that Isl1 + CPCs contribute to both myocardium and endocardium (Cai et al., 2003; Laugwitz et al., 2008; Sun et al., 2007) by virtue of providing a first visual in situ evidence for sequential transitions of multipotent Isl1 + progenitors to the respective lineage-committed progenitors and, in turn, to terminally-differentiated progeny of myocardium and endocardium. In this respect, our study complements lineage-tracing analyses that by nature come short of identifying intermediate stages in the differentiation cascade. Further, the study defines the precise place (i.e., the distal OFT) and time (i.e., the E9.5-E10.5 developmental interval) when these fate decisions take place. The findings are in keeping with a recent study identifying the distal OFT as the 'zone of commitment' where cardiomyocyte commitment to Hopx-expressing cardiomyoblasts takes place (Jain et al., 2015) . While the latter study focuses on signals specifying cardiomyoblast commitment, our study focuses on endocardial commitment, establishing a role for VEGF signaling in this process. Because external cues promoting a pro-cardiomyocytic fate and external cues promoting a pro-endocardial fate of bipotent progenitors must to be well-balanced, we sought to examine the outcome of perturbations in the developmentally-programmed VEGF dosage, assuming that VEGF might govern endocardial fate. Methodologically, we considered VEGF GOF to be more informative approach than a VEGF LOF approach for two reasons: first, while VEGF LOF via Flk1 knock-out has already shown to result in complete absence of endocardium, early embryonic lethality precludes addressing possible causes of endocardial loss (Shalaby et al., 1995) . Second, due to the normal stoichiometry of cardiomyocytes vastly outnumbering endocardial cells, only a VEGF GOF approach (and a resultant exaggerated allocation to endocardialcommitted progenitors) could have allowed observing the reciprocal effect of under-representation of myocardial progenitors and its culmination in myocardial thinning.
Several lines of evidence support the conclusion that the apparent abnormal phenotype of an expanded endocardium and reduced myocardium is indeed initiated at the progenitor level: First, the ratio of lineage-committed progenitors detected in the OFT is clearly skewed in favor of endocardial-committed progenitors. Second, the possibilities that endocardial expansion might be due to a VEGF-induced proliferative advantage and, conversely, that myocardial thinning is due to VEGF-induced myocardial toxicity were ruled-out. Third, inducing VEGF after bipotent Isl1 + progenitors have been committed resulted in neither surplus endocardium nor in myocardial deficit, but instead led to a different, unrelated phenotype. The study uncovered a novel role of VEGF in heart development, namely, in the control of fate decisions made by Isl1 + /Flk1 + CPCs. It would be of interest to determine whether VEGF might also play a role in other dichotomous developmental fate decisions, like in the case of Flk1 + hemangioblasts known to give rise to both hematopoietic stem cells and endothelium (Choi et al., 1998) . Developmentallyprogrammed VEGF dosage is exquisitely controlled and even a relatively small deviation from its normal dosage might cause severe developmental abnormalities and embryonic lethality (Carmeliet et al., 1996; Carmeliet et al., 1999; Ferrara et al., 1996) . Notably, the source of VEGF in the OFT transition zone is the myocardium. Thus, it is conceivable that there is a negative feedback loop in which a critical mass of myocardial cells produces a sufficient amount of VEGF to prevent further myocardial differentiation. VEGF polymorphisms and mutations likely to affect VEGF dosage were indeed associated with congenital defects in ventricular outflow track, endocardial cushion formation and heart septation. VEGF levels are also likely to be affected by gestational hypoxia that, in turn, might contribute to developmental heart defects (Dor et al., 2001; Qing et al., 2007) . Findings reported here uncovering a previously unappreciated VEGF function underscore a need to uncover the full spectrum of VEGF activities in heart development.
Experimental procedures
Transgenic mice and conditional modulations of VEGF expression in heart
A bi-transgenic system for heart-specific, tetracycline-regulated transgene expression was used. The driver heart specific myosin heavy chain-α promoter (MHCα)-tTA mouse (Yu et al., 1996) and the responder pTET-VEGF 165 transgenic line (Dor et al., 2002 ) were previously described. Progeny of MHCα-tTA ± /pTET-VEGF +/+ crosses were genotyped by PCR and mice inheriting only one transgene serving as littermate controls. VEGF was induced by withdrawing tetracycline (500 μg/ml, Teva Pharmaceutical Industries Ltd., Israel) from the drinking water and, when indicated, de-induced by tetracycline re-addition (the 'Tet-off' system) (Dor et al., 2002) . Embryos were staged as E0.5 by the morning of observing a vaginal plug and staging verified by somite count. All mice were housed in a specific pathogen-free (SPF) facility with a 12-hour light/12-hour dark cycle and fed with irradiated food and tetracycline-containing water ad libitum. Mice were sacrificed following intraperitoneal injection of sodium pentobarbital. All animal experiments conform to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health, and were performed under approval of the Hebrew University Ethics Committee (approval no. MD-10127064).
In situ mRNA hybridization
4% paraformaldehyde-fixed, paraffin-embedded embryos were sectioned at 10 μm for in situ hybridization (ISH). Radioactive ISH was performed using 35 S-labeled antisense riboprobes as described previously (Dor et al., 2001) . Brightfield and darkfield images were captured using a DP70 cooled CCD digital camera (Olympus, Japan) mounted on a Zeiss Axioshkop microscope (Zeiss, Germany).
VEGF ELISA
VEGF protein levels in fetal heart tissues were measured using mouse VEGF Quantikine ELISA kit (R&D System, USA) according to the manufacturer's instructions. Values given are means of protein Note no change in frequency of myocardial cells but a significant increase in the frequency of endocardial/endothelial cells. n = 15. C. Representative sections through the ventricle wall of E13.5 hearts reveal no perturbation in pattern of myocardium and endocardium layering but a significantly higher density of coronary vessels. Scale bar: 100 μm. ***P ≤ 0.001; n. s., nonsignificant; two-tailed Student's t-test.
concentration normalized by total concentration of protein (Quick Start™ Bradford, Bio-Rad, USA).
In situ immuno-histochemistry
Embryos were fixed with 4% PFA, and embedded in paraffin. Sections (5 μm) were rehydrated and antigen was retrieved in a citrate buffer (pH = 6.0) by microwaving at 92°C for 20 min. Sections were blocked with CAS-Block™ Histochemical Reagent (Thermo Fisher Scientific, USA) at room temperature followed by overnight incubation with the respective primary antibody. Endocardial cells were visualized by using Isolectin B4 (IB4) (L2140, 1:20, Sigma, USA) staining. Sections were mounted using a DAPI mounting medium (Lab Vision™ PermaFluor™ Aqueous Mounting Medium, Thermo Scientific, USA).
Immunostaining of wholemount heart specimens was performed using the protocol as described (Ahnfelt-Ronne et al., 2007) with the following modifications: the embryonic hearts (up to E13.5) were fixed in 4% PFA for 2 h and permeabilized for 1 h at room temperature with 1% Triton X 100 (Sigma, USA).
The following primary antibodies were used: mouse monoclonal anti-myosin heavy chain (MHC) antibody (ab15, 1:100, Abcam, UK), goat polyclonal anti-Nkx-2.5 antibody (sc-8697, 1:100, Santa Cruz, USA), rabbit monoclonal anti-VEGF antibody (M3281, ready-to-use, Spring Bioscience, USA), rabbit monoclonal anti-VEGF receptor 2 (Flk1) antibody (#2479, 1:200, Cell Signaling Technology, USA), rat monoclonal anti-CD31 antibody (#550274, 1:50, BD Biosciences, USA), mouse monoclonal anti-Isl1 antibody (39.4D5, 1:50, DSHB, USA), rabbit monoclonal anti-Ki67 antibody (#RM-9106S, 1:200, Thermo Scientific, USA), rabbit polyclonal anti-cleaved caspase-3 (C-Casp3) antibody (#9661, Cell Signaling Technology, USA). Secondary antibodies were Cy2-conjugated streptavidin, anti-mouse and anti-goat; Cy3-and Cy5-conjugated anti-mouse and anti-rabbit antibodies (1:400, Jackson ImmunoResearch, USA). Sections and wholemount tissue were analyzed under a fluorescence microscope (Nikon, ECLIPSE Ni-U, Japan) using NIS-Elements imaging software. Z-stacks were done on a × 10 air objective and at 2 μm intervals.
Flow cytometry
Embryonic hearts were dissected in ice-cold Dulbecco's Phosphate Buffered Saline (PBS) and digested in 0.5% PBS/BSA containing 0.125% collagenase II (Worthington, USA) and 1 μg/ml DNase I at 37°C for 40 min with gentle shaking at 300 r.p.m. Single cell suspensions from digested tissues were stained for the indicated intracellular antigens (CD45, Ter119 and CD31) and cell surface antigen (MF20) according to the Flow Cytometry-Best Protocols® (eBioscience, USA). Antibodies used were anti-CD45 Pacific Blue (#103126, 1:200, BioLegend, USA), anti-Ter119 Pacific Blue (#116232, 1:200, BioLegend), anti-CD31 APC (-0311, 1:250, eBioscience), and anti-myosin heavy chain Alexa Fluor 488 (#53-6503, 1:100, eBioscience). Flow cytometry analysis was performed using a MACSQuant Analyzer 10 (Miltenyi Biotec., Germany).
Statistical analysis
Numerical data were analyzed using two-tailed Student's t-test at P ≤ 0.05. Graphs were generated using GraphPad Prism 6.0. Data are presented as mean ± s.e.m.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.mod.2016.10.004.
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